Close to a year after Forma Therapeutics' executive team hammered out a partnership with Celgene packed with $200 million in early-stage payouts, the big biotech outfit has come back with a $600 million discovery deal that might eventually lead the pair to the M&A altar.
Johnson & Johnson has formally accepted the Carlyle Group's $4 billion-plus bid to snatch up its Ortho Clinical Diagnostics arm, more than two months after announcing the proposed transaction.
CRO giant Icon has agreed to trade $143.5 million for Aptiv Solutions, looking to complement its own technology in complex trial design and expand its presence in Japan.
The day after Baxter announced it will split its biopharma and medical products, an analyst is calling for U.K. devicemaker Smith & Nephew to follow suit.
Baxter International is the latest life sciences player to see better living through mitosis, unveiling a plan to separate its drug development arm from its sprawling med tech business in hopes of helping each grow faster.
Japan is the second largest drug market after the U.S., and Western drugmakers are giving it new attention as growth slows elsewhere. AstraZeneca has upped its bet there, paying Sumitomo Chemical about $102 million to buy full control of its Japanese subsidiary AstraZeneca KK.
Hot on the trail of new M&A deals, Stryker finalized its acquisition of Patient Safety Technologies. The Kalamazoo, MI-based company paid $120 million for the medical device outfit, gaining access to Patient Safety's line of trackable surgical tools.
Sanofi CEO Chris Viehbacher may be reconsidering his November plans to spend just €1 billion to €2 billion per year on acquisitions. Rumor has it the drug giant is eyeing a bid for Merck's OTC unit, which could sell for up to $12 billion.
GE Healthcare completed its acquisition of three Thermo Fisher Scientific units. The $1.1 billion deal gives GE access to Thermo Fisher's profitable cell culture, gene modulation and magnetic bead businesses, helping the company expand its presence in protein analysis and medical diagnostics.
AMRI has inked a deal to trade $41 million for contract manufacturer Cedarburg Pharmaceuticals, looking to broaden its capabilities in the sector and home in on API production.